CORCEPT THERAPEUTICS INC — Director's Dealing 2025

Nov 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2025-11-03

Reporting Person: Lyon Joseph Douglas (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-03	Common Stock	M	5000	$13.56	Acquired	15277	Direct
2025-11-03	Common Stock	S	5000	$73.6489	Disposed	10277	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-03	Stock option (right to buy)	$13.56	M	5000	Disposed	2030-02-07	Common Stock (5000)	Direct

Footnotes

F1: Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

F2: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.

F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $73.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F4: Fully exercisable.